Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Next Previous
Search
Trial Profile

Phase II Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Emtora Biosciences

    • Most Recent Events

    • 26 Apr 2024 According to a Biodexa Pharmaceuticals media release, company entered into a definitive agreement with Rapamycin Holdings Inc. (d/b/a Emtora Biosciences) for the rights to eRapa under an exclusive, worldwide license (with the ability to grant sublicenses) to develop, manufacture, commercialize and otherwise advance the clinical potential of eRapa. The Phase 2 study in NMI Bladder Cancer supported by $3 million grant from National Cancer Institute, part of the National Institutes of Health
    • 26 Apr 2024 According to a Biodexa Pharmaceuticals media release, Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 2025.
    • 22 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top